Relay Therapeutics is a clinical-stage biotechnology company leveraging computational modeling and structure-based drug design to develop precision small molecule therapies. The company differentiates itself through proprietary technology platforms and strategic collaborations, aiming to address unmet needs in oncology and genetic diseases. With a pipeline of innovative candidates and partnerships with industry leaders, Relay Therapeutics is positioned to advance next-generation targeted therapies.Operates ...

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The fireside chats will be webcast live and may be accessed through Relay Therapeutic ...

Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company deve ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Relay Therapeutics, Inc. (NASDAQ:RLAY) is the next best biotech stock on our list. TheFly reported on January 26 that Oppenheimer upgraded RLAY from Perform to Outperform and set a $14 price target. The firm said the upcoming VIKTORIA-1 trial readout for Celcuity’s gedatolisib could act as a positive catalyst for mutant-selective inhibitors such as RLAY’s zovegalisib. Oppenheimer expects the VIKTORIA-1 results to fall short of ...

Group 1 - Oppenheimer upgraded Relay Therapeutics Inc. (RLAY) to Outperform from Perform, resulting in a significant increase in stock price since the upgrade on the 26th [1] - The stock price of Relay Therapeutics has seen a considerable boost following the upgrade, indicating positive market sentiment [1] Group 2 - The focus of the analysis is on identifying promising biotechnology companies that are innovating through unique mechanisms of action, first-in-class therapies, or platform technologies [1] - The approach emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]

Group 1 - Oppenheimer upgraded Relay Therapeutics Inc. (RLAY) to Outperform from Perform, resulting in a significant increase in the stock price since the upgrade on the 26th [1] - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The focus is on identifying promising biotechnology companies that innovate through unique mechanisms, first-in-class therapies, or platform technologies [1] Group 2 - The analyst emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and market opportunities while balancing financial fundamentals [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector, which can yield significant returns but requires careful scrutiny [1]

Core Insights - Relay Therapeutics announced interim clinical data for zovegalisib, an investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα, showing promising efficacy in patients with metastatic breast cancer [1][10] Efficacy Data - The median progression-free survival (PFS) was reported as 10.3 months for all patients and 11.4 months for second-line (2L) patients [6] - Among patients with measurable disease, the objective response rate (ORR) was 39%, while the ORR for 2L patients was 47% [6] - Efficacy was consistent across various subsets, with a median PFS of 11.4 months and ORR of 44% for patients who received prior SERD [7] Patient Population - As of October 15, 2025, 118 patients were enrolled in the zovegalisib + fulvestrant arm of the ReDiscover study, with significant prior therapy levels noted [4] - Among the 64 patients receiving 600mg twice daily, 44% had two or more prior lines of therapy, and 29% had detectable ESR1 mutations at baseline [4] Ongoing Trials - The Phase 3 ReDiscover-2 trial is ongoing, focusing on zovegalisib + fulvestrant in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced breast cancer [8] - The ReDiscover trial is also evaluating zovegalisib in combination with fulvestrant and CDK inhibitors [3] Company Overview - Relay Therapeutics is a clinical-stage company focused on developing precision medicine therapies for cancer and genetic diseases, with zovegalisib being its lead program [12] - The company utilizes its Dynamo platform to discover and develop mutant-selective inhibitors of PI3Kα, addressing a significant patient population in the U.S. [10][12]

Core Insights - Insider transactions can be influenced by company policies rather than personal conviction, as demonstrated by the recent share sales of Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics [1][10][11] Transaction Summary - Peter Rahmer sold 40,529 shares of Relay Therapeutics for approximately $299,900, which is about 10.72% of his direct holdings before the transaction [2][3] - The transaction size was significantly larger than his recent median sell size of 12,103 shares and the historical median of 1,352 shares per sale [4] - Post-transaction, Rahmer holds 337,469 shares valued at around $2.5 million [2] Context of the Sale - The direct holdings of Rahmer decreased by approximately 34% from April 29, 2024, to October 29, 2025 [5] - Shares were sold at an average price of $7.30 and $7.50 on October 28 and 29, 2025, respectively, with the stock closing at $7.40 on October 29, 2025 [6] Company Overview - Relay Therapeutics is a clinical-stage biotechnology company focused on precision drug discovery in oncology and genetic diseases, utilizing advanced computational modeling [8] - The company has a pipeline that includes RLY-4008 (FGFR2 inhibitor), RLY-2608 (PI3Ka inhibitor), and RLY-1971 (SHP2 inhibitor) [9] - As of October 29, 2025, the market capitalization of Relay Therapeutics is $1.19 billion, with a revenue of $8.4 million for the trailing twelve months [7] Recent Developments - Relay Therapeutics announced improved financials in its latest earnings results on November 6, although it missed analyst revenue estimates [13] - Changes to the board of directors were also announced, indicating potential shifts in company strategy [13]

Core Insights - Commodore Capital increased its stake in Relay Therapeutics by approximately 3.65 million shares during Q3, raising its total holdings to 17 million shares valued at $88.7 million [2][7] - Relay Therapeutics now constitutes 4.3% of Commodore Capital's reported U.S. equity assets under management (AUM) [3][7] - Relay's share price has risen 60% over the past year, significantly outperforming the S&P 500, which increased by 13% in the same timeframe [3] Company Overview - Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision small molecule therapeutics targeting specific cancers and genetic diseases [5] - The company has a market capitalization of $1.3 billion and reported revenue of $8.4 million over the trailing twelve months (TTM) [4] - Relay's TTM net income stands at a loss of $297.6 million [4] Financial Performance - The company reduced its quarterly net loss to $74.1 million from $88.1 million year-over-year, indicating improved financial management [6] - Relay Therapeutics has a cash reserve of $596 million, which is projected to sustain operations until 2029 [6] Pipeline and Market Position - Relay Therapeutics is advancing multiple candidates in clinical trials, particularly in oncology and genetic diseases, with a focus on FGFR2-altered tumors and other specific cancer types [5][6] - Despite a 60% increase in share price over the past year, Relay's shares remain nearly 90% below their 2021 highs, highlighting the volatility in early-stage therapeutics [9]

Core Insights - Relay Therapeutics is currently focused on executing Phase III clinical trials for its asset RLY-2608, which is a selective inhibitor for PI3K-alpha mutant, believed to be the first of its kind in clinical development [2] - The company is exploring various triplet regimens for potential use in earlier lines of breast cancer treatment and has begun dosing patients with PI3K-alpha-driven vascular malformations [2] - Relay Therapeutics has a strong financial position with close to $600 million on its balance sheet, indicating potential for value generation in the coming years [2]